计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Eganelisib (IPI-549), PI3 激酶 p110-γ亚基抑制剂
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Information
Eganelisib (IPI-549) is a potent inhibitor ofPI3K-γwith >100-fold selectivity over other lipid and protein kinases. The biochemicalIC50for PI3K-γ is 16 nM.
In vitro
IPI-549 is found to be a remarkably tight binder to PI3K-γ with a Kd of 290 pM and >58-fold weaker affinity for other Class I PI3K isoforms. It does not significantly inhibit a panel of 468 mutant and nonmutant protein and lipid kinases (including Class II PI3K isoforms) at 1 μM. In PI3K-α, -β, -γ, and -δ dependent cellular phospho-AKT assays, IPI-549 demonstrates excellent PI3K-γ potency (IC50 = 1.2 nM) and selectivity against other Class I PI3K isoforms (>146-fold). Furthermore, IPI-549 dose dependently inhibits PI3K-γ-dependent bone marrow-derived macrophage (BMDM) migration in vitro. IPI-549 is also found to be selective against a panel of 80 GPCRs, ion channels, and transporters at 10 μM. In vitro, IPI-549 shows moderate to high cell permeability across Caco-2 cell monolayers, is slowly metabolized in cultured hepatocytes (t1/2 > 360 min), and demonstrates IC50s greater than 20 μM for the CYP isoforms tested (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4).
In vivo
In vivo (mice, rats, dog, and monkeys), IPI-549 has excellent oral bioavailability, low clearance, and distributes into tissues with a mean volume of distribution of 1.2 L/kg. It has a favorable pharmacokinetic profile to allow potent and selective inhibition of PI3K-γ in vivo. IPI-549 can significantly reduce neutrophil migration in a dose-dependent manner in mouse model when administered orally at all of the tested doses. In addition, IPI-54 has been shown to inhibit tumor growth in murine syngeneic models through alteration of immune cells in the tumor microenvironment.
Cell Data
cell lines：
Concentrations：--
Incubation Time：30 min
Powder Purity:≥99%
规格
别名
伊加尼利西布 (IPI-549)
英文别名
Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-
规格或纯度
Moligand™, 10mM in DMSO
英文名称
Eganelisib (IPI-549)
生化机理
Eganelisib（IPI-549）是一种强效的 PI3K-γ 抑制剂，与其他脂质和蛋白激酶相比，其选择性大于 100 倍。PI3K-γ 的生化 IC50 值为 16 nM。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
PI3 激酶 p110-γ亚基抑制剂
名称和识别符
EC号
864-707-3
分子类型
小分子
Isomeric SMILES
C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
分子量
528.56
Reaxy-Rn
28088877
Reaxys-RN link address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=28088877&ln=
技术文档
高级数据
产品属性
| IC50 | PI3Kγ, IC50: 16 nM |
|---|---|
| ALogP | 2.732 |
| hba_count | 5 |
| HBD Count | 2 |
| Rotatable Bond | 6 |
关联靶点（人）
PIK3CG
Tclin
磷脂酰肌醇 4,5-双磷酸 3-激酶催化亚基 γ 异构体(Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform)
(1 活性数据)
PIK3CA
Tclin
磷脂酰肌醇 4,5-双磷酸 3-激酶催化亚基 α 异构体(Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform)
(1 活性数据)
PIK3CB
Tchem
磷脂酰肌醇 4,5-双磷酸 3-激酶催化亚基 β 异构体(Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform)
(1 活性数据)
PIK3CD
Tclin
磷脂酰肌醇 4,5-双磷酸 3-激酶催化亚基 delta 异构体(Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform)
(1 活性数据)
化学和物理性质
溶解性
Solubility (25°C) In vitro DMSO: 61 mg/mL (132.16 mM); Water: Insoluble; Ethanol: Insoluble;
DMSO(mg / mL) Max Solubility
100
DMSO(mM) Max Solubility
189.1932799
Water(mg / mL) Max Solubility
＜1
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）